mGlu4 allosteric modulation for treating Parkinson's disease
Keywords: Parkinson's disease; Dyskinesia; Glutamate; Dopamine; mGlu4; 6-OHDA; 6-hydroxydopamine; ADX88178; 4-methyl-N-[5-methyl-4-(1H-pyrazol-4-yl)-1,3-thiazol-2-yl]pyrimidin-2-amine; AIM; abnormal involuntary movements; CODA-RET; complemented donor acceptor reson